The resources are already there in China - Eddingham. Problem is that this might blow over before you come up with an acceptable trial design and enroll patients - even then, they'll likely either die or recover before V's anti-inflammatory properties have a chance to make a diff in their outcomes. This kind of experiment would really only work in the US for patients who are already on V and don't have multiple comorbidities, i.e. relatively healthy older patients.
News 
Market Data 
Discover 
